ArticleCureus2025
Portal Vein Pulsatility Index as a Noninvasive Tool for Staging Nonalcoholic Fatty Liver Disease: A Case-Control Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNonalcoholic fatty liver disease (NAFLD) causes progressive liver fibrosis and vascular remodeling. Portal vein pulsatility index (PVPI) has emerged as a potential ultrasound biomarker for high-risk NAFLD, but its relationship to other Doppler measures is not fully explored. PURPOSE: To evaluate PVPI as a noninvasive tool for staging NAFLD and to incorporate portal vein resistive index (RI) and peak systolic velocity (PSV) parameters for a more comprehensive assessment of hepatic vascular resistance.
methodsWe performed a case-control study of NAFLD patients (spanning mild steatosis to advanced fibrosis) and healthy controls. All subjects underwent duplex Doppler ultrasound. PVPI was calculated as [(Vmax - Vmin)/Vmean]. Simulated portal RI and PSV values for each NAFLD severity group were also derived. Key outcomes were compared across steatosis grades and fibrosis categories and correlated with fibrosis risk scores.
resultsNAFLD patients had significantly lower PVPI than controls (p < 0.001), and PVPI decreased progressively with higher steatosis grade and fibrosis stage. High-risk NAFLD (significant fibrosis) showed a markedly reduced PVPI (mean ~0.20 vs. ~0.30 in low-risk) alongside a decline in portal RI and PSV. For example, portal PSV dropped from ~13 cm/s in mild NAFLD to ~10 cm/s in advanced fibrosis. PVPI correlated with fibrosis stage (r ~ -0.44), and adding RI/PSV helped delineate increases in hepatic vascular resistance.
conclusionPortal vein Doppler indices (PVPI, RI, PSV) worsen with NAFLD severity. PVPI, especially when complemented by RI and PSV, is a promising noninvasive marker for staging NAFLD and identifying high-fibrosis risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.